Please login to the form below

Not currently logged in
Email:
Password:

Sally Waterman appointed as chair of OBN

She succeeds David Laskow-Pooley

OBN Sally WatermanOBN has appointed Sally Waterman as its new chair, succeeding David Laskow-Pooley with immediate effect.

Waterman has been a member of OBN's board of directors since January 2014 when she joined as a non-executive director. She has over 25 years of experience in the life sciences industry and currently serves as senior vice president of corporate development at Abzena, a biopharmaceuticals company.

Prior to this, Waterman has held several operational and research and development positions including chief operating officer for PolyTherics, director of research and development at Protherics and director of development operations at Xenova.

Laskow-Pooley said: “I am delighted that Sally will be succeeding me as chair. Her extensive experience of the life sciences sector, her significant board experience and her personal qualities will be invaluable to OBN.”

Laskow-Pooley stepped down as chair after eight years in the role and will continue on at OBN as a non-executive director.

Waterman added: “On behalf of OBN and the board I would like to thank David for the enormous contribution he has made to the development and success of OBN and wish him well with his future plans, both in the UK and USA.”

16th March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics